Skip to main content
    A

    Atrium Therapeutics, Inc. Common Stock (RNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.48
    +0.05 (+0.78%)

    Market Cap: $162.00M

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Atrium Therapeutics, Inc. Common Stock (RNA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Atrium Therapeutics, Inc. Common Stock (RNA) has a market cap of $162.00M and an enterprise value of $118.12M. Its share count is down 87.64% from a year earlier. It kept -229.67% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 27.09% below the market cap, as cash exceeds debt.

    Market Cap$162.00M
    Enterprise Value$118.12M
    Latest price (Nov 17, 2026)$6.48

    Key Dates

    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.40% in the quarter ended Sep 30, 2026 and shrank 62.84% a year over 2 years.

    Shares Outstanding17.04M
    Shares Change (YoY)-87.64%
    Shares Change (QoQ)-0.40%
    Share Count Growth (2Y CAGR)-62.84%

    Valuation Ratios

    Sales and book value multiples are 2.8x and 0.5x. Its year-end P/S ranged from 69.1x to 395.2x from 2020 to 2025.

    P/S Ratio2.8x
    Forward P/S3.9x
    P/B Ratio0.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 90.85% over 52 weeks and trades 22.86% below its 50-day average.

    Beta (1Y)1.38
    52-Week Change-90.85%
    1-Month Change-14.85%
    3-Month Change-52.74%
    6-Month Change-49.96%
    5-Year Change-63.24%
    Total Return (1Y)-90.85%
    Total Return (3Y CAGR)+0.57%
    Total Return (5Y CAGR)-25.74%
    Return vs SPY (1Y)-102.41%
    Max Drawdown (1Y)-91.18%
    Max Drawdown (3Y)-91.18%
    Sharpe Ratio (1Y)-1.44
    Correlation with SPY (1Y)0.11
    50-Day Average$8.40
    200-Day Average$16.99
    52-Week Range$6.36 to $16.77
    RSI (14 Days)23.6
    Average Volume (20 Days)232.48K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 10.46x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio10.46x
    Quick Ratio10.46x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on invested capital is -44.51% over the last 12 months, against a 5-year average of -32.91%.

    Return on Equity (ROE)-43.49%
    Return on Assets (ROA)-33.77%
    Return on Invested Capital (ROIC)-44.51%
    ROE (5Y Average)-32.40%
    ROA (5Y Average)-27.17%
    ROIC (5Y Average)-32.91%
    Asset Turnover0.14x
    Receivables Turnover5.18x

    Scores

    RNA has an Altman Z-Score of 1.12, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score1.12
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $38.82M over the last 12 months is up 86.02% from the 12 months before.

    Revenue$38.82M
    Revenue Growth (YoY)+86.02%
    Gross Profit$16.38M
    Operating Income-$94.56M
    Pretax Income-$89.12M
    Net Income-$89.15M
    Reported EPS (TTM)-$3.99

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 77.66% of the $263.99M in total assets.

    Cash and Equivalents$44.56M
    Total Debt$679.00K
    Net Cash$43.89M
    Net Cash Per Share$2.58
    Working Capital$233.39M
    Shareholder Equity$205.02M
    Book Value Per Share$12.03
    Total Assets$263.99M
    Total Liabilities$58.97M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $3.43M of capital spending, operating cash flow left -$83.12M of free cash flow.

    Operating Cash Flow-$79.69M
    Capital Expenditures$3.43M
    Free Cash Flow-$83.12M
    FCF Per Share-$3.85
    Depreciation and Amortization$968.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -243.60%.

    Gross Margin42.18%
    Operating Margin-243.60%
    Pretax Margin-229.58%
    Net Margin-229.67%
    FCF Margin-214.11%
    Gross Margin (5Y Average)95.60%

    Growth

    Revenue grew 26.38% a year over 3 years.

    Revenue Growth (3Y CAGR)+26.38%
    Revenue Growth (5Y CAGR)+22.36%
    Book Value Per Share Growth (2Y CAGR)+35.63%
    Tangible Book Per Share Growth (2Y CAGR)+35.63%

    Revenue and profit by year

    Dividends and Yields

    RNA does not pay a dividend. Its free cash flow yield is -75.29%.

    FCF Yield-75.29%
    Shareholder Yield0.00%

    Peer Position

    Against 7 similar companies, RNA has the 7th highest P/S.

    P/S Ratio2.8x vs 11.8x median
    ROIC-44.51% vs 116.36% median
    Revenue Growth (Trailing 4 Quarters, YoY)+86.02% vs +21.28% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -53.65% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-53.65%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RNA

    What is RNA's market cap?

    Atrium Therapeutics, Inc. Common Stock has a market cap of $162.00M. Its enterprise value, which adds debt and subtracts cash, is $118.12M.

    How many shares of RNA are outstanding?

    Atrium Therapeutics, Inc. Common Stock has 17.04M shares outstanding. The count is down 87.64% from a year earlier.

    Does RNA pay a dividend?

    No. Atrium Therapeutics, Inc. Common Stock does not pay a dividend.

    How much debt does RNA have?

    Atrium Therapeutics, Inc. Common Stock has $679.00K of total debt and $44.56M of cash and equivalents, a net cash position of $43.89M.